Vertex Inc. (VERX)
Compared to Estimates, Vertex (VERX) Q2 Earnings: A Look at Key Metrics
The headline numbers for Vertex (VERX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Vertex (VERX) Q2 Earnings and Revenues Top Estimates
Vertex (VERX) came out with quarterly earnings of $0.2 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.15 per share a year ago.
Vertex Gears Up to Report Q2 Earnings: What Can Investors Expect?
VRTX heads into its Q2 earnings release with Trikafta, Alyftrek, Casgevy and Journavx in focus as investors watch product sales and updates on ongoing pipeline studies.
Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse
Vertex Pharmaceuticals NASDAQ: VRTX said it has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, a transaction Vertex executives described as a strategic expansion into specialty endocrinology.
Vertex's Crinetics Deal Balances Growth with Integration Risk
Vertex Pharmaceuticals NASDAQ: VRTX recently announced its plans to acquire Crinetics Pharmaceuticals NASDAQ: CRNX for $10 billion. The deal, which has already been approved by the board of directors of both companies, is expected to close in the third quarter of 2026.
Crinetics shares surge after Vertex agrees to $10B cash buyout
Crinetics Pharmaceuticals shares surged after Vertex Pharmaceuticals announced an agreement to acquire the endocrinology-focused biotech company in a deal valued at approximately $10 billion. The all-cash transaction values Crinetics at $85 per share and is expected to close during the current quarter, subject to customary conditions.
Vertex to buy Crinetics in $10 billion deal
Vertex Pharmaceuticals will buy Crinetics Pharmaceuticals for a total equity value of about $10 billion, the companies said on Monday.
Vertex Gets FDA Nod for Expanded Use of Casgevy in SCD & TDT
VRTX gets FDA approval to expand Casgevy use in patients aged two and older with SCD or TDT, a first for genetic therapies in both inherited blood disorders.
Vertex Pharmaceuticals Has One Of The Widest And Most Durable Moats In Biotech
Vertex Pharmaceuticals Incorporated maintains a dominant, monopoly position in cystic fibrosis, driving highly predictable, recurring revenue and justifying its valuation premium. VRTX is leveraging its CF cash flows to expand into pain, hematology, and renal franchises, with promising catalysts in each area, notably Pove for IgAN. Non-CF franchises are gaining traction, with Journavx and Casgevy contributing to revenue growth; renal (Pove) is positioned to become a major driver post-2027.
Vertex Pharmaceuticals: Povetacicept May Redefine Growth Narrative (Rating Upgrade)
Vertex Pharmaceuticals Incorporated's R&D success extends beyond its cystic fibrosis franchise. VRTX's Povetacicept could be approved by the FDA as early as November 30th for the treatment of an autoimmune disease called immunoglobulin A nephropathy. On the other hand, despite the high commercial expectations for Journavx and Casgevy, demand remains soft.
Can Vertex's Kidney Pipeline Power Its Next Growth Phase?
VRTX is betting on kidney disease candidates like povetacicept and inaxaplin to drive long-term growth beyond its dominant cystic fibrosis franchise.
Madrigal Pharmaceuticals Could Become The Next Vertex
Madrigal Pharmaceuticals, Inc. is a high-risk/high-reward play, focused solely on MASH with its first-in-class drug Rezdiffra. Rezdiffra's initial U.S. TAM is expanding, with diagnosis rates and label extensions potentially driving revenue to double-digit billions over the next decade. Competition from Novo Nordisk's Wegovy and upcoming Efruxifermin poses significant long-term risk, but MDGL enjoys a near-term lead and first-mover advantage.
